Towa Pharmaceutical Co., Ltd.

TSE:4553.T

3015 (JPY) • At close November 5, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) JPY.

20232022202120202019201820172016201520142013201220112010200920082007200620052004
Revenue 227,934208,859165,615154,900110,384105,10493,43084,94982,11571,47061,35155,24148,71946,14539,043.5235,966.81231,495.47229,235.19824,193.83924,763.379
Cost of Revenue 146,551136,14595,42989,44859,73856,70550,37945,90240,26134,48731,12127,50021,98621,34818,793.97118,345.84916,519.00815,588.92913,236.28213,625.766
Gross Profit 81,38372,71470,18665,45250,64648,39943,05139,04741,85436,98330,23027,74126,73324,79720,249.54917,620.96314,976.46413,646.26910,957.55711,137.613
Gross Profit Ratio 0.3570.3480.4240.4230.4590.460.4610.460.510.5170.4930.5020.5490.5370.5190.490.4760.4670.4530.45
Reseach & Development Expenses 13,24215,26511,48810,6428,5667,9167,7259,3528,9246,1445,2964,47800000000
General & Administrative Expenses 00000000000000000000
Selling & Marketing Expenses 00000000000000000000
SG&A 63,73551,93440,16034,88125,90924,20023,68222,55212,26119,72317,14415,48200000000
Other Expenses 525907724527468572899357414708391479718-184-182.528223.051-287.631277.145917.65896.972
Operating Expenses 63,73567,19950,98045,52734,50332,43131,40732,17630,71925,87722,52320,01817,62415,14212,504.7511,212.8879,690.7749,229.5658,560.3528,402.988
Operating Income 17,6485,51419,20519,92316,14315,96811,6436,86911,13411,1057,7067,7239,1099,6557,744.7996,408.0765,285.694,416.7042,397.2052,734.625
Operating Income Ratio 0.0770.0260.1160.1290.1460.1520.1250.0810.1360.1550.1260.140.1870.2090.1980.1780.1680.1510.0990.11
Total Other Income Expenses Net 6,811-9103,707-1,2014,5382,602-1,810367-1,2324,1009951,587624-220-410.752-164.042-710.082-53.111-119.836348.441
Income Before Tax 24,4594,60522,24618,72820,70918,8869,8337,2379,90315,2068,7029,3109,7339,4357,334.0476,244.0344,575.6084,363.5932,277.3693,083.066
Income Before Tax Ratio 0.1070.0220.1340.1210.1880.180.1050.0850.1210.2130.1420.1690.20.2040.1880.1740.1450.1490.0940.125
Income Tax Expense 8,2862,4046,3314,7706,2065,4103,3381,6612,2194,0882,7103,1093,9953,5892,732.0892,466.9051,882.7591,765.4921,265.0131,095.31
Net Income 16,1732,20115,91413,95814,50313,4756,4955,5767,68411,1185,9926,2015,7375,8464,601.9583,777.1292,692.8492,598.1011,012.3561,987.756
Net Income Ratio 0.0710.0110.0960.090.1310.1280.070.0660.0940.1560.0980.1120.1180.1270.1180.1050.0850.0890.0420.08
EPS 328.5844.72323.35283.62294.72253.32122.03113.32154.19218.07117.54121.62111.49113.5389.3673.3452.2850.4418.4940.03
EPS Diluted 328.5843.72316.19271.93272.61253.32122.03104.74145.43218.07117.54121.62111.49113.5389.3673.3452.2850.4418.4940.03
EBITDA 35,53627,03531,69431,67525,70525,89121,38115,79019,69918,18213,83313,24212,50811,3729,409.828,567.5146,674.5596,250.6724,417.3423,724.07
EBITDA Ratio 0.1560.1290.1910.2040.2330.2460.2290.1860.240.2540.2250.240.2570.2460.2410.2380.2120.2140.1830.15